Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.310
-0.070 (-2.07%)
Nov 18, 2026, 10:50 AM EST - Market open
Aclaris Therapeutics Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $13 → $12 | Buy | Maintains | $13 → $12 | +262.54% | Nov 17, 2026 |
| Wedbush | Wedbush | Hold Downgrades $8 → $3 | Hold | Downgrades | $8 → $3 | -9.37% | Nov 17, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Reiterates $4 | Hold | Reiterates | $4 | +20.85% | Nov 16, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $16 | Buy | Reiterates | $16 | +383.38% | Nov 16, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +202.11% | Nov 6, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $12 | Buy | Reiterates | $12 | +262.54% | Oct 29, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +171.90% | Oct 28, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 | Buy | Maintains | $11 | +232.33% | Oct 19, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.